Anti-vascular endothelial growth factor (anti-VEGF) agents have revolutionized the treatment of various ophthalmological conditions, including age-related macular degeneration (AMD), diabetic macular edema, and retinal vessel occlusion [1]. The gene discussed is VEGFA; the disease is age-related macular degeneration.